EP3033150A4 - Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types - Google Patents

Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types Download PDF

Info

Publication number
EP3033150A4
EP3033150A4 EP14836702.2A EP14836702A EP3033150A4 EP 3033150 A4 EP3033150 A4 EP 3033150A4 EP 14836702 A EP14836702 A EP 14836702A EP 3033150 A4 EP3033150 A4 EP 3033150A4
Authority
EP
European Patent Office
Prior art keywords
karenitecin
administration
resistant
types
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14836702.2A
Other languages
German (de)
French (fr)
Other versions
EP3033150A1 (en
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of EP3033150A1 publication Critical patent/EP3033150A1/en
Publication of EP3033150A4 publication Critical patent/EP3033150A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14836702.2A 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types Withdrawn EP3033150A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865360P 2013-08-13 2013-08-13
PCT/US2014/050463 WO2015023551A1 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

Publications (2)

Publication Number Publication Date
EP3033150A1 EP3033150A1 (en) 2016-06-22
EP3033150A4 true EP3033150A4 (en) 2017-06-28

Family

ID=52468603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14836702.2A Withdrawn EP3033150A4 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

Country Status (2)

Country Link
EP (1) EP3033150A4 (en)
WO (3) WO2015023552A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202643B2 (en) 2011-10-31 2019-02-12 University Of Utah Research Foundation Genetic alterations in glioma
US20180122507A1 (en) * 2015-04-14 2018-05-03 University Of Utah Research Foundation Genetic alterations in ovarian cancer
CN105198790B (en) * 2015-04-20 2018-02-16 范国煌 Promote the tetracyclic compound of double negative t cells in-vitro multiplication
ES2905208T3 (en) * 2016-01-27 2022-04-07 Fraunhofer Ges Forschung Means and methods for staging, typing and treatment of a cancerous disease
CN107058315B (en) 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application
EP3642351A1 (en) * 2017-06-20 2020-04-29 Nantomics, LLC USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC
CN113461952B (en) * 2021-06-30 2022-07-01 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Active oxygen response type self-degradation polymer and preparation method and application thereof
CN118103949A (en) * 2021-09-15 2024-05-28 英飞凌科技有限责任公司 Method for integrating SONOS into HKMG stream

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (en) * 2004-04-27 2005-12-01 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968607B1 (en) * 2005-12-02 2014-01-15 Nabil Habib Lab Treatment of cancer and other diseases
US9023805B2 (en) * 2010-09-16 2015-05-05 Bionumerik Pharmaceuticals, Inc. Increasing cancer patient survival time by administration of dithio-containing compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (en) * 2004-04-27 2005-12-01 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNEMARIE H. VAN HATTUM ET AL: "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 2, 15 October 2000 (2000-10-15), pages 260 - 266, XP055007980, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q *
MUNSTER PAMELA N ET AL: "Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 20, no. 11, November 2011 (2011-11-01), pages 1565 - 1574, XP002766330 *
NAUMANN R WENDEL ET AL: "Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 71, no. 11, 1 January 2011 (2011-01-01), pages 1397 - 1412, XP009165133, ISSN: 0012-6667, DOI: 10.2165/11591720-000000000-00000 *
See also references of WO2015023551A1 *

Also Published As

Publication number Publication date
WO2015023551A1 (en) 2015-02-19
WO2015023552A1 (en) 2015-02-19
WO2015023553A2 (en) 2015-02-19
WO2015023553A3 (en) 2015-04-23
EP3033150A1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
EP3558324A4 (en) Cyclic dinucleotide sting agonists for cancer treatment
EP3033150A4 (en) Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
EP3119908A4 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
EP3062808A4 (en) Treatment of metastatic prostate cancer
EP3268465A4 (en) Methods of cancer treatment using activated t cells
EP3197518A4 (en) Medicament preparation and treatment devices, methods, and systems
EP3071209A4 (en) Use of sting agonist as cancer treatment
EP3004877A4 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
EP3076977A4 (en) Combination therapy for treating cancer
EP3076972A4 (en) Cancer treatment with combination of plinabulin and taxane
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
MX2015011606A (en) Methods of treating cancer and preventing cancer drug resistance.
EP3024375A4 (en) Medical device, and the methods of using same
EP3432888A4 (en) Treatment of cancer with tg02
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
EP3307329A4 (en) Cancer treatment and diagnosis
WO2014138364A3 (en) Methods of treating and preventing cancer drug resistance
EP3180000A4 (en) Cancer diagnosis and therapy
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
EP3004396A4 (en) Methods and compositions for the treatment of cancer
EP3007557A4 (en) Preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
EP3062790A4 (en) Pharmaceutical combinations for the treatment of cancer
EP3008212A4 (en) Methods of treatment of cancer
EP3364987A4 (en) Prognosis and treatment of squamous cell carcinomas
EP3011013A4 (en) Methods for treatment of ovarian cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAUSHEER, FREDERICK H.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20170130BHEP

Ipc: A61K 31/185 20060101ALI20170130BHEP

Ipc: A61K 31/4745 20060101AFI20170130BHEP

Ipc: A61P 35/00 20060101ALI20170130BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170526

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20170519BHEP

Ipc: A61K 31/185 20060101ALI20170519BHEP

Ipc: A61K 31/4745 20060101AFI20170519BHEP

Ipc: A61P 35/00 20060101ALI20170519BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20170614BHEP

Ipc: A61K 31/185 20060101ALI20170614BHEP

Ipc: A61K 31/4745 20060101AFI20170614BHEP

Ipc: A61K 45/06 20060101ALI20170614BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CROWN BIOSCIENCE, INC.

17Q First examination report despatched

Effective date: 20190405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190817